QuantCapitol. Congressional Trading Intelligence

Updated 2026-11-05 08:10 UTC · Public disclosure record

EWTICKER

Edwards Lifesciences Corp.

BULLISH stock

Congress has disclosed 18 buys and 15 sells of EW (Edwards Lifesciences Corp.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.

Activity Congressional Activity

18
Buy
15
Sell
+3
Net
15
Active politicians

Round-trip watch Still on the books

Members who disclosed buying EW and have not disclosed selling, versus their own entry (the most recent disclosed buy). "Open" means no disclosed sale — never "still holds" — and the % is unrealised, on paper. Not investment advice.

MemberEntry (last buy)Entry priceNowvs entryStatus
Rob Bresnahan 2025-04-08 $67.07 $92.01 +37.2% in profit
Alan Armstrong 2026-03-27 $79.34 $92.01 +16.0% in profit
Rohit Khanna 2026-05-01 $83.98 $92.01 +9.6% in profit

Price as of 2026-10-30. Counted open while disclosed buys outnumber disclosed sells; tracks the price, not exact position size (amounts are ranges).

Price & congressional trades
Buy Sell

Fundamentals · FY2026 Valuation

Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for Health. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.

P/E
52.78
▲ pricier than Health (median 29.7)
how it's calculated
P/E = price ÷ earnings per share
$92.01 ÷ $1.74 = 52.78
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
P/B
4.99
▲ pricier than Health (median 4.4)
how it's calculated
P/B = price ÷ book value per share
$92.01 ÷ $18.42 = 4.99
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
EV/EBITDA
31.59
▲ pricier than Health (median 16.2)
how it's calculated
EV/EBITDA = (market cap + net debt) ÷ EBITDA — net cash lowers EV
($53.0B − $2.3B net cash) ÷ $1.6B = $50.7B ÷ $1.6B = 31.59
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.

Legislation Related Legislation

Recent bills in this stock's sector (Health). Sector-level context from Congress.gov — a bill names a policy area, not this company specifically.

BillTitlePolicy areaLatest action
HR 10887 Protecting Consumer Access to Generic Drugs Act of 2026 Health 2026-10-22
HR 10874 Medicare Low Income Subsidy Equality Act of 2026 Health 2026-10-22
HR 10858 CARE for Blood Cancer Act of 2026 Health 2026-10-22
HR 10810 National Patient Safety Board Act of 2026 Health 2026-10-15
HR 10824 Stroke Education and EMS Care Improvement Act of 2026 Health 2026-10-15

33 trades Recent Congressional Trades

Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.

PoliticianChamberTypeOwnerDateDisclosure lagPrice move
in that
window
AmountScoreSource
Rohit Khanna House BUY OCR ◆ insider divergence · moderate Child 2026-05-01 38 days +2.2% $1K–$15K 13.9 ↗ filing
Alan Armstrong Senate BUY ◆ insider divergence · moderate Self 2026-03-27 116 days +6.6% $1K–$15K 99.1 ↗ eFD
Josh Gottheimer House SELL ◆ insider convergence · moderate Joint · Morgan Stanley - Select UMA Account # 1 2025-11-19 15 days -0.3% $1K–$15K
<0.1% of NW
27.3 ↗ filing
Bruce Westerman House SELL ◆ insider convergence Self · Fisher IRA 2025-04-21 7 days +9.2% $1K–$15K
0.7% of NW
30.1 ↗ filing
Rob Bresnahan House BUY ◆ insider divergence · moderate Self · JP Morgan Brokerage Account 2025-04-08 0 days 0.0% $1K–$15K
0.2% of NW
64.4 ↗ filing
Bruce Westerman House BUY ◆ insider divergence Self · Fisher IRA 2025-03-03 14 days -1.1% $1K–$15K
0.7% of NW
65.4 ↗ filing
Rohit Khanna House BUY OCR ◆ insider divergence Child 2024-10-14 24 days -5.4% $1K–$15K 10.6 ↗ filing
Rohit Khanna House BUY OCR ◆ insider divergence Child 2024-09-09 23 days -0.9% $1K–$15K 15.7 ↗ filing
Mike Kelly House SELL ◆ insider divergence · strong Spouse 2024-04-11 34 days — $1K–$15K
0.1% of NW
97.3 ↗ filing
Josh Gottheimer House BUY ◆ insider divergence Joint · Morgan Stanley - Select UMA Account # 1 2023-12-11 24 days — $1K–$15K
<0.1% of NW
86.8 ↗ filing
Rohit Khanna House BUY OCR ◆ insider divergence Child 2023-12-05 30 days — $1K–$15K 31.8 ↗ filing
John Curtis House SELL ◆ insider convergence Joint · Northwestern Mutual - Joint 2023-12-04 0 days — $1K–$15K 22.3 ↗ filing
Rohit Khanna House BUY OCR ◆ insider divergence Child 2023-08-29 7 days — $1K–$15K 40.4 ↗ filing
Rohit Khanna House BUY OCR ◆ insider divergence Child 2023-08-11 25 days — $1K–$15K 75.9 ↗ filing
John Curtis House BUY ◆ insider divergence · moderate Joint · Northwestern Mutual - Joint 2023-06-21 26 days — $1K–$15K 40.4 ↗ filing
Zoe Lofgren House SELL ◆ insider convergence Spouse · John Marshall Collins Rollover IRA 2023-05-25 12 days — $1K–$15K
0.1% of NW
10.6 ↗ filing
John Curtis House BUY ◆ insider divergence Joint · Northwestern Mutual - Joint 2023-04-26 6 days — $1K–$15K 75.9 ↗ filing
Daniel Goldman House BUY ◆ insider divergence · moderate Self · Daniel Goldman Grandchildren 1986 Trust > TACS R3K 2023-03-06 28 days — $15K–$50K
<0.1% of NW
90.9 ↗ filing
Katherine Clark House SELL Spouse 2021-09-16 27 days — $1K–$15K
0.1% of NW
22.3 ↗ filing
Zoe Lofgren House BUY Spouse 2021-09-02 35 days — $1K–$15K
0.1% of NW
15.7 ↗ filing
Zoe Lofgren House BUY Spouse 2021-08-09 31 days — $1K–$15K
0.1% of NW
22.3 ↗ filing
Katherine Clark House SELL Spouse 2021-07-27 17 days — $1K–$15K
0.1% of NW
40.4 ↗ filing
Peter Meijer House SELL Self 2021-02-16 3 days — $1K–$15K 40.4 ↗ filing
Peter Meijer House SELL Self 2021-01-28 6 days — $1K–$15K 75.9 ↗ filing
Katherine Clark House BUY Spouse 2020-11-05 53 days — $1K–$15K
0.1% of NW
75.9 ↗ filing
Zoe Lofgren House SELL Spouse 2020-03-23 0 days — $1K–$15K
0.1% of NW
40.4 ↗ filing
Gilbert Cisneros House SELL Self 2019-07-30 9 days — $1K–$15K
0.1% of NW
75.9 ↗ filing
Susie Lee House SELL Joint 2019-03-20 12 days — $1K–$15K
0.2% of NW
75.9 ↗ filing
Lamar Smith House SELL Self 2017-11-01 33 days — $1K–$15K 22.3 ↗ filing
Zoe Lofgren House BUY Spouse 2017-06-15 27 days — $1K–$15K
0.1% of NW
75.9 ↗ filing
Lamar Smith House SELL Self 2017-06-12 21 days — $1K–$15K 40.4 ↗ filing
Lamar Smith House BUY Self 2016-12-12 22 days — $1K–$15K 75.9 ↗ filing
Michael Conaway House SELL Spouse 2014-02-14 6 days — $1K–$15K 75.9 ↗ filing

Corporate insiders · SEC Form 4 Insider Activity

What the company's own officers and directors did in EW — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →

4
Congress trades with insider convergence
14
…with insider divergence
223
Insider open-market trades

Of the congressional trades in EW, 4 coincided with corporate insiders moving the same way within 60 days, and 14 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.

DateInsiderRoleTypeSizeSource
2026-10-08 Lippis Daniel J. Other SELL 10b5-1 $53K ↗ EDGAR
2026-09-11 Lippis Daniel J. Other SELL 10b5-1 $54K ↗ EDGAR
2026-08-31 Dahl Andrew M. Other SELL $50K ↗ EDGAR
2026-08-28 Bruls Annette Other SELL $238K ↗ EDGAR
2026-08-26 Markowitz Wayne Other SELL $113K ↗ EDGAR
2026-08-26 Chopra Daveen Other SELL $106K ↗ EDGAR
2026-08-26 Chopra Daveen Other SELL $2.8M ↗ EDGAR
2026-08-11 Lippis Daniel J. Other SELL 10b5-1 $57K ↗ EDGAR
2026-07-30 Markowitz Wayne Other SELL $13K ↗ EDGAR
2026-07-28 Markowitz Wayne Other SELL $819K ↗ EDGAR
2026-07-27 Zovighian Bernard J C-suite SELL $245K ↗ EDGAR
2026-07-10 Lippis Daniel J. Other SELL 10b5-1 $57K ↗ EDGAR
2026-06-30 Lippis Daniel J. Other SELL 10b5-1 $57K ↗ EDGAR
2026-06-17 Zovighian Bernard J C-suite SELL 10b5-1 $46K ↗ EDGAR
2026-05-29 Dahl Andrew M. Other SELL $49K ↗ EDGAR
2026-05-27 BOBO DONALD E JR Other SELL $2.0M ↗ EDGAR
2026-05-22 Chopra Daveen Other SELL $127K ↗ EDGAR
2026-05-18 Lippis Daniel J. Other SELL 10b5-1 $50K ↗ EDGAR
2026-05-15 BOBO DONALD E JR Other SELL $818K ↗ EDGAR
2026-05-15 BOBO DONALD E JR Other SELL $655K ↗ EDGAR
2026-05-12 Zovighian Bernard J C-suite SELL 10b5-1 $66K ↗ EDGAR
2026-05-12 Zovighian Bernard J C-suite SELL 10b5-1 $2.8M ↗ EDGAR
2026-05-11 Markowitz Wayne Other SELL $47K ↗ EDGAR
2026-05-04 Lippis Daniel J. Other SELL 10b5-1 $86K ↗ EDGAR
2026-05-01 Lippis Daniel J. Other SELL 10b5-1 $2K ↗ EDGAR

Combined timeline — Congress & insiders

Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.

DateWhoTypeSize
◆ insider 2026-10-08 Lippis Daniel J. Other 10b5-1 SELL $53K
◆ insider 2026-09-11 Lippis Daniel J. Other 10b5-1 SELL $54K
◆ insider 2026-08-31 Dahl Andrew M. Other SELL $50K
◆ insider 2026-08-28 Bruls Annette Other SELL $238K
◆ insider 2026-08-26 Markowitz Wayne Other SELL $113K
◆ insider 2026-08-26 Chopra Daveen Other SELL $106K
◆ insider 2026-08-26 Chopra Daveen Other SELL $2.8M
◆ insider 2026-08-11 Lippis Daniel J. Other 10b5-1 SELL $57K
◆ insider 2026-07-30 Markowitz Wayne Other SELL $13K
◆ insider 2026-07-28 Markowitz Wayne Other SELL $819K
◆ insider 2026-07-27 Zovighian Bernard J C-suite SELL $245K
◆ insider 2026-07-10 Lippis Daniel J. Other 10b5-1 SELL $57K
◆ insider 2026-06-30 Lippis Daniel J. Other 10b5-1 SELL $57K
◆ insider 2026-06-17 Zovighian Bernard J C-suite 10b5-1 SELL $46K
◆ insider 2026-05-29 Dahl Andrew M. Other SELL $49K
◆ insider 2026-05-27 BOBO DONALD E JR Other SELL $2.0M
◆ insider 2026-05-22 Chopra Daveen Other SELL $127K
◆ insider 2026-05-18 Lippis Daniel J. Other 10b5-1 SELL $50K
◆ insider 2026-05-15 BOBO DONALD E JR Other SELL $818K
◆ insider 2026-05-15 BOBO DONALD E JR Other SELL $655K
◆ insider 2026-05-12 Zovighian Bernard J C-suite 10b5-1 SELL $66K
◆ insider 2026-05-12 Zovighian Bernard J C-suite 10b5-1 SELL $2.8M
◆ insider 2026-05-11 Markowitz Wayne Other SELL $47K
◆ insider 2026-05-04 Lippis Daniel J. Other 10b5-1 SELL $86K

FAQ Common questions

How much has Congress traded EW?

18 disclosed buys and 15 sells of EW (Edwards Lifesciences Corp.) appear in official congressional financial disclosures.

Is it legal for members of Congress to trade EW?

Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.

Where does this data come from?

Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.

About this data. Sourced from official House Clerk and Senate eFD financial disclosures (Senate via a maintained community mirror — see project documentation). Transaction amounts are reported as ranges, not exact figures. Interest scores, consensus labels, and backtested performance are proprietary analytical calculations based on public data and are not investment advice. Backtested performance is a hypothetical simulation, not actual portfolio performance.